Difference between revisions of "Editorial Board"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Allogeneic HSCT conditioning regimens" to "Allogeneic HSCT") |
Warner-admin (talk | contribs) m (Text replacement - "Autologous HSCT conditioning regimens" to "Autologous HSCT") |
||
Line 153: | Line 153: | ||
|style="background-color:#efedf5"|[[Allogeneic HSCT]] | |style="background-color:#efedf5"|[[Allogeneic HSCT]] | ||
|- | |- | ||
− | |style="background-color:#efedf5"|[[Autologous HSCT | + | |style="background-color:#efedf5"|[[Autologous HSCT]] |
|- | |- | ||
|style="background-color:#efedf5"|[[Graft versus host disease (GVHD)]] | |style="background-color:#efedf5"|[[Graft versus host disease (GVHD)]] |
Revision as of 13:25, 14 October 2017
Please feel free to contact us with any questions or inquiries, at [email protected].
Editor-in-Chief
Peter C. Yang, MD Boston, MA Twitter: Hem_Onc |
Deputy Editor
Jeremy L. Warner, MD, MS Nashville, TN Twitter: Hemoncwarner |